Intelligence · Clinical Development
Pipeline search results
Programs matching “alcohol” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 117 pipeline programs matching "alcohol" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Aramchol
Galmed Pharmaceuticals
Non-Alcoholic Fatty Liver Disease
1 trial -
Arbaclofen Placarbil
Indivior Pty Ltd
Alcohol Use Disorder
1 trial -
Arvisol placebo, Arvisol 150mg
Pari Pharma GmbH
Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt
1 trial -
Bovine colostrum
Hospital Authority, Hong Kong
Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54
1 trial -
CF102
Can-Fite BioPharma
Non-alcoholic Steatohepatitis (NASH)
1 trial -
CMND-100
Clearmind Medicine
Alcohol Use Disorder
1 trial -
CRV431 75mg
Hepion Pharmaceuticals
NASH - Nonalcoholic Steatohepatitis
1 trial -
Comparator: MK0594 5 mg/day
VYNE Therapeutics
Alcohol Dependence
1 trial -
D7830C00004
AstraZeneca AB
Non-cirrhotic non-alcoholic steatohepatitis with fibrosis
1 trial -
Disulfiram
BRIGHT MINDS BIOSCIENCES INC.
Alcohol-Related Disorders
1 trial -
EDP-305 1.5 mg
ENANTA PHARMACEUTICALS INC
Non-Alcoholic Steatohepatitis
1 trial -
EDP-305 Dose 1
ENANTA PHARMACEUTICALS INC
Non-Alcoholic Steatohepatitis
1 trial -
Efinopegdutide
Merck KGaA, Darmstadt, Germany
Non-alcoholic Fatty Liver Disease
1 trial -
Efinopegdutide 20 mg/mL
Merck KGaA, Darmstadt, Germany
Nonalcoholic Fatty Liver Disease
1 trial -
GIP/GLP-1a
United Therapeutics Europe Ltd
Non-Alcoholic Fatty Liver Disease
1 trial -
GR-MD-02
GALECTIN THERAPEUTICS INC
Nonalcoholic Steatohepatitis
1 trial -
HEC96719
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Non-Alcoholic Steatohepatitis
1 trial -
ICONICplus
The George Institute
Alcohol dependence
1 trial -
ION224
IONIS PHARMACEUTICALS INC
Steatohepatitis, Nonalcoholic
1 trial -
K-001-201
The George Institute
Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
1 trial -
LIK066
Novartis Pharmaceuticals
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
1 trial -
MGL-3196
Madrigal Pharmaceuticals EU Limited
Non-alcoholic Steatohepatitis
1 trial -
MI-CBT
BRIGHT MINDS BIOSCIENCES INC.
Alcohol Abuse
1 trial -
MI/CBT
BRIGHT MINDS BIOSCIENCES INC.
Alcoholic, Marijuana Misuse
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.